Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · IEX Real-Time Price · USD
10.56
-0.27 (-2.49%)
At close: Jul 2, 2024, 4:00 PM
10.48
-0.08 (-0.76%)
After-hours: Jul 2, 2024, 7:55 PM EDT
Roivant Sciences Revenue
In the fiscal year ending March 31, 2024, Roivant Sciences had annual revenue of $124.80M with 103.65% growth. Revenue in the quarter ending March 31, 2024 was $28.93M with 5.68% year-over-year growth.
Revenue (ttm)
$124.80M
Revenue Growth
+103.65%
P/S Ratio
62.51
Revenue / Employee
$137,439
Employees
908
Market Cap
7.80B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 124.80M | 63.52M | 103.65% |
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Henry Schein | 12.45B |
| Bio-Rad Laboratories | 2.61B |
| Exact Sciences | 2.53B |
| Chemed | 2.29B |
| HealthEquity | 1.04B |
| Ascendis Pharma | 357.63M |
| Legend Biotech | 342.80M |
ROIV News
- 4 weeks ago - Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - GlobeNewsWire
- 2 months ago - Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis - Business Wire
- 3 months ago - Roivant's anti-inflammatory drug succeeds in mid-stage study - Reuters
- 3 months ago - Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - GlobeNewsWire
- 5 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - GlobeNewsWire
- 6 months ago - Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 7 months ago - Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - GlobeNewsWire